NCT06927232View on ClinicalTrials.gov

AZA+Lus VS AZA Monotherapy in HR-MDS

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Higher-risk Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine (AZA)

Azacitidine 75mg/m/ day \*5 days, 28 days for 1 course

DRUG

Luspatercept

Luspatercept 1.0 mg/kg subcutaneously every 3 weeks, adjusted according to hemoglobin, up to 1.75mg/kg. If hemoglobin ≥120g/L, luspatercept can be discontinued.

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER